Innovent Biologics

Innovent Biologics is one of China's most innovative biopharmaceutical companies, focused on developing affordable cancer immunotherapies and biologics. The company's PD-1 inhibitor Tyvyt was the first domestically developed PD-1 therapy approved in China. Innovent has extensive partnerships with Eli Lilly and other global pharma companies, and is expanding its pipeline into autoimmune diseases and metabolic disorders.

Innovent represents China's ambition to become a global leader in biologic drug innovation, not just manufacturing, with a pipeline that increasingly targets global markets.